{
 "method": [
  {
   "value": "124",
   "label": "comments from 108 submitters, 7 January 2025 to 6 June 2026"
  },
  {
   "value": "48",
   "label": "submitters whose asks we could read, each counted once"
  },
  {
   "value": "74 of 74",
   "label": "ask quotes found word for word in the saved comment or letter"
  }
 ],
 "hint": "Open a request to see who asked for it, in their own words. The highlight marks the ask; each card links to the comment on Regulations.gov.",
 "rows": [
  {
   "id": "monitoring",
   "label": "How to monitor a model and when to revalidate it",
   "count": 21,
   "records": [
    {
     "title": "Invaryant",
     "meta": [
      "CRO, vendor or consultancy",
      "8 January 2025",
      "3 comments"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Specify metrics for acceptable performance thresholds and triggers for reassessment of AI models in a regulatory context.",
       "mark": [
        0,
        121
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0007",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Consumer Healthcare Products Association",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "Recommendation 3: FDA should provide clear guidance on what constitutes a significant model change requiring revalidation or reassessment of model credibility, especially for models used in cGMP systems or quality control.",
       "mark": [
        0,
        222
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0088",
     "urlLabel": "Read the comment"
    },
    {
     "title": "ACRO",
     "meta": [
      "Trade or professional group",
      "4 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "We ask the Agency to consider including examples of successfully and effectively implemented lifecycle monitoring programs in the final guidance, by sharing anonymized case studies of lifecycle monitoring approaches and plans it has had the opportunity to evaluate in regulatory submissions.",
       "mark": [
        0,
        291
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0045",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Eigen Bio",
     "meta": [
      "Drug or biotech company",
      "18 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Lifecycle monitoring of output confidence under real-world deployment drift.",
       "mark": [
        0,
        76
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0112",
     "urlLabel": "Read the comment"
    },
    {
     "title": "American Society of Hematology",
     "meta": [
      "Trade or professional group",
      "9 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "Pre-planning for risk mitigation, especially data drift, is necessary, as well as clear guidance for the model risk assessment process.",
       "mark": [
        0,
        135
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0109",
     "urlLabel": "Read the comment"
    },
    {
     "title": "International Society for Pharmacoepidemiology",
     "meta": [
      "Trade or professional group",
      "3 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Summary of its letter, on its website",
       "text": "We also stressed the importance of lifecycle management, especially for self-evolving systems, and recommended the establishment of a centralized, public-facing repository of validated AI models, similar to the EU AI Act’s registry for high-risk models, to enhance transparency and reusability.",
       "mark": [
        0,
        294
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0034",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Personalized Medicine Coalition",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "The guidance should further identify opportunities within the change management planning process for developers to receive prospective input from the Agency.",
       "mark": [
        0,
        157
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0082",
     "urlLabel": "Read the comment"
    },
    {
     "title": "RWE Alliance",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "We suggest FDA expand its sections on credibility assessments and life cycle management to include examples for self-learning models, foundation models, and generative AI.",
       "mark": [
        0,
        171
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0084",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Advarra",
     "meta": [
      "CRO, vendor or consultancy",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Summary of its letter, on its website",
       "text": "AI is not static—models evolve, data shifts, and performance can degrade over time.",
       "mark": [
        0,
        83
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0086",
     "urlLabel": "Read the comment"
    },
    {
     "title": "CognifAI Solutions",
     "meta": [
      "CRO, vendor or consultancy",
      "21 February 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "We suggest the FDA develop a framework to assess and monitor the fairness of AI algorithms, including guidelines on how to report and mitigate any detected biases throughout the lifecycle of AI tools.",
       "mark": [
        0,
        200
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0018",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Nexus Concordat",
     "meta": [
      "CRO, vendor or consultancy",
      "12 May 2026",
      "2 comments"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "I respectfully request that the FDA consider these proposals, particularly within the Step 4 (Model Description and Evaluation) and Section IV.B (Life Cycle Maintenance) portions of the framework, and recognize compiler-verified synthetic twins as a distinct architectural category in a final version of the guidance or in companion guidance.",
       "mark": [
        146,
        168
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0120",
     "urlLabel": "Read the comment"
    },
    {
     "title": "PharmAgility Consulting Group",
     "meta": [
      "CRO, vendor or consultancy",
      "4 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "We also encourage the FDA to further emphasize the importance of ongoing performance verification and reverification throughout the AI lifecycle.",
       "mark": [
        0,
        145
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0044",
     "urlLabel": "Read the comment"
    },
    {
     "title": "LUNGevity Foundation",
     "meta": [
      "Patient or consumer group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "The draft guidance notes that some steps of the credibility assessment may need to be re-executed.",
       "mark": [
        0,
        98
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0098",
     "urlLabel": "Read the comment"
    },
    {
     "title": "National Alliance for Hispanic Health",
     "meta": [
      "Patient or consumer group",
      "9 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Identify and address any data drift or performance degradation by gender, race, ethnicity, and socioeconomic status.",
       "mark": [
        0,
        116
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0108",
     "urlLabel": "Read the comment"
    },
    {
     "title": "National Health Council",
     "meta": [
      "Patient or consumer group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "Accordingly, FDA guidance should clearly mandate continuous, comprehensive post-market monitoring to promptly detect, evaluate, and correct any degradation or drift in model performance.28",
       "mark": [
        0,
        188
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0083",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Elvan Ceyhan",
     "meta": [
      "Academic or research institute",
      "6 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "The guidance touches on model drift (in the form of data drift) but lacks a structured approach for AI model revalidation when performance degrades over time.",
       "mark": [
        0,
        158
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0061",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Rominder Singh (Northeastern University)",
     "meta": [
      "Academic or research institute",
      "16 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Recommendations: Referring to the FDA DHAC meeting in 2024—which focused on generative AI in medical devices—it would be helpful to include discussion on premarket evaluation, risk management, and postmarket monitoring.",
       "mark": [
        0,
        219
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0111",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Srijit Seal (Broad Institute)",
     "meta": [
      "Academic or research institute",
      "27 January 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Data drift must also be addressed during model evaluation, using metrics that align with those used for performance evaluation.",
       "mark": [
        0,
        127
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0013",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Fayez Rahman",
     "meta": [
      "Individual",
      "9 January 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Question: Regarding model risk, is it fair to say that the risk decreases over time since the ML component is being trained with more data so there should be less bias moving forward therefore periodic review can decrease in frequency, and dependency on release can be increased?",
       "mark": [
        0,
        279
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0010",
     "urlLabel": "Read the comment"
    },
    {
     "title": "George Evgrafov",
     "meta": [
      "Individual",
      "7 April 2025",
      "10 comments"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "The draft acknowledges that AI models may change over time (e.g., via retraining), but does not sufficiently define how life cycle maintenance should be handled in regulated settings.",
       "mark": [
        0,
        183
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0069",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Lamia Anwar",
     "meta": [
      "Individual",
      "30 September 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "The discussion on lifecycle maintenance appropriately highlights data drift, but does not provide quantitative thresholds for when retraining or revalidation is required.",
       "mark": [
        0,
        170
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0116",
     "urlLabel": "Read the comment"
    }
   ],
   "note": "21 of 48 readable submitters"
  },
  {
   "id": "training-data",
   "label": "What FDA expects of training data",
   "count": 21,
   "records": [
    {
     "title": "American Society of Hematology",
     "meta": [
      "Trade or professional group",
      "9 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "Just as clinical trials report subject demographics, AI models should disclose dataset composition, so investigators have a clear understanding of the information used to generate the AI results.",
       "mark": [
        0,
        195
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0109",
     "urlLabel": "Read the comment"
    },
    {
     "title": "ACRO",
     "meta": [
      "Trade or professional group",
      "4 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "ACRO asks the Agency to consider including further discussion and elaboration in the final guidance of how to achieve fit for use, representative data in the not uncommon situation where absence of bias and representativeness is, in practice, difficult to demonstrate.",
       "mark": [
        0,
        268
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0045",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Consumer Healthcare Products Association",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "This could include recommendations for ensuring data sufficiency, representativeness, and strategies to mitigate bias in non-traditional datasets.",
       "mark": [
        0,
        146
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0088",
     "urlLabel": "Read the comment"
    },
    {
     "title": "International Society for Pharmacoepidemiology",
     "meta": [
      "Trade or professional group",
      "3 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Summary of its letter, on its website",
       "text": "Lastly, we called for greater attention to model provenance and governance, encouraging the FDA to consider frameworks from organizations like the National Telecommunications and Information Administration (NTIA) and to set clear expectations around documentation, versioning, and traceability that are proportional to the model’s risk and regulatory impact.",
       "mark": [
        0,
        205
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0034",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Personalized Medicine Coalition",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "To help mitigate biases in AI, developers and regulators should prioritize efforts to ensure training data is reflective of the intended population and account for shortcomings in health data throughout the product development lifecycle.",
       "mark": [
        0,
        237
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0082",
     "urlLabel": "Read the comment"
    },
    {
     "title": "RWE Alliance",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "We recommend that FDA continue placing emphasis on the importance of diverse, high-quality datasets and the necessity of mechanisms for detecting and mitigating AI bias, as such biases could impact clinical outcomes significantly.",
       "mark": [
        0,
        230
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0084",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Advarra",
     "meta": [
      "CRO, vendor or consultancy",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Summary of its letter, on its website",
       "text": "The draft guidance touches on “fit-for-use” data, but additional detail is lacking on:",
       "mark": [
        0,
        86
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0086",
     "urlLabel": "Read the comment"
    },
    {
     "title": "CognifAI Solutions",
     "meta": [
      "CRO, vendor or consultancy",
      "21 February 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "We urge the FDA to provide clear guidance on how data sets should be curated to avoid biases, including specific methods to assess representativeness across key patient subgroups (e.g., racial, ethnic, and gender diversity).",
       "mark": [
        0,
        224
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0018",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Invaryant",
     "meta": [
      "CRO, vendor or consultancy",
      "8 January 2025",
      "3 comments"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Provide more detailed examples of \"fit-for-use\" datasets, particularly for underrepresented populations to minimize bias.",
       "mark": [
        0,
        121
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0006",
     "urlLabel": "Read the comment"
    },
    {
     "title": "PharmAgility Consulting Group",
     "meta": [
      "CRO, vendor or consultancy",
      "4 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "While the draft appropriately emphasizes the need for trustworthy and transparent systems, further clarity on data provenance would provide essential direction to developers and users.",
       "mark": [
        0,
        184
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0044",
     "urlLabel": "Read the comment"
    },
    {
     "title": "LUNGevity Foundation",
     "meta": [
      "Patient or consumer group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "In addition to opportunities for consultation with the FDA, sponsors could benefit from greater clarity in the final guidance on considerations for AI model development, particularly in ensuring the training data for a proposed AI model are fit for use.",
       "mark": [
        0,
        253
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0098",
     "urlLabel": "Read the comment"
    },
    {
     "title": "National Alliance for Hispanic Health",
     "meta": [
      "Patient or consumer group",
      "9 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Line 91-96: The discussion on data quality should include a mandate for transparency in the demographic composition of datasets.",
       "mark": [
        0,
        128
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0108",
     "urlLabel": "Read the comment"
    },
    {
     "title": "National Health Council",
     "meta": [
      "Patient or consumer group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "These datasets should encompass multiple clinical trials or observational studies, reflecting diverse patient demographics, disease presentations, and care settings.",
       "mark": [
        0,
        165
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0083",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Critical Path Institute",
     "meta": [
      "Academic or research institute",
      "4 April 2025"
     ],
     "tags": [
      {
       "label": "Press report"
      }
     ],
     "quotes": [
      {
       "label": "RAPS, reporting the letter",
       "text": "The group also asked for clarification on handling missing and out of bounds (OOB) data.",
       "mark": [
        0,
        88
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0048",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Elvan Ceyhan",
     "meta": [
      "Academic or research institute",
      "6 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "While the guidance stresses data quality, it does not mention synthetic data as a potential solution for bias mitigation.",
       "mark": [
        0,
        121
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0061",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Rominder Singh (Northeastern University)",
     "meta": [
      "Academic or research institute",
      "16 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "The committee’s recommendations on data bias, hallucination risks, and the need for transparency in AI development should be incorporated.",
       "mark": [
        0,
        138
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0111",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Anonymous (0060)",
     "meta": [
      "Individual",
      "6 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "These can include the clear documentation of AI model architecture and training data sources, conducting model performance assessments, and applying fairness metrics to avoid overlooking safety concerns.",
       "mark": [
        0,
        203
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0060",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Fayez Rahman",
     "meta": [
      "Individual",
      "9 January 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "I am hoping the guideline specifies that the use of generic and public LLMs should not be permissible due to bias and erros.",
       "mark": [
        0,
        124
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0010",
     "urlLabel": "Read the comment"
    },
    {
     "title": "George Evgrafov",
     "meta": [
      "Individual",
      "6 April 2025",
      "10 comments"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "While the guidance emphasizes the need for data used in model development to be relevant, representative, and of high quality, it does not provide clear recommendations for situations where data provenance is not fully known or cannot be verified.",
       "mark": [
        0,
        247
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0055",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Lamia Anwar",
     "meta": [
      "Individual",
      "30 September 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "However, explicit guidance on assessing and mitigating algorithmic bias, particularly for underrepresented populations (e.g., pediatrics, rare diseases), would strengthen regulatory confidence in AI outputs.",
       "mark": [
        0,
        207
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0116",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Stephen Lewack",
     "meta": [
      "Individual",
      "8 January 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Part of this guidance has to be around how data is validated and where secure repositories of validated data can be accessed.",
       "mark": [
        0,
        125
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0004",
     "urlLabel": "Read the comment"
    }
   ],
   "note": "21 of 48 readable submitters"
  },
  {
   "id": "risk-score",
   "label": "A clearer way to score model risk",
   "count": 20,
   "records": [
    {
     "title": "Consumer Healthcare Products Association",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "Recommendation 1: We recommend that FDA include a tiered framework or decision-tree with illustrative examples of low-, medium-, and high-risk AI model applications.",
       "mark": [
        0,
        165
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0088",
     "urlLabel": "Read the comment"
    },
    {
     "title": "George Evgrafov",
     "meta": [
      "Individual",
      "6 April 2025",
      "10 comments"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "The concept of AI model risk is central to the framework, yet the guidance provides limited detail on how to consistently determine risk levels.",
       "mark": [
        0,
        144
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0056",
     "urlLabel": "Read the comment"
    },
    {
     "title": "ACRO",
     "meta": [
      "Trade or professional group",
      "4 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "It would be helpful to see additional anonymized case examples of how to think about model risk from previous submissions FDA has received.",
       "mark": [
        0,
        139
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0045",
     "urlLabel": "Read the comment"
    },
    {
     "title": "American Society of Hematology",
     "meta": [
      "Trade or professional group",
      "9 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "Therefore, we recommend that the FDA provide clear guidance as to who or what entity determines the model risk, to provide documentation of the risk assessment, and we suggest that the guidance provide enhanced definitions of Decision Consequence and Model Influence.",
       "mark": [
        0,
        267
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0109",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Consumer Technology Association",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "We urge FDA to adopt a risk-based approach for AI technologies in both drug/biologics and medical device guidance, with clear frameworks for evaluating risk.",
       "mark": [
        0,
        157
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0085",
     "urlLabel": "Read the comment"
    },
    {
     "title": "International Society for Pharmacoepidemiology",
     "meta": [
      "Trade or professional group",
      "3 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Summary of its letter, on its website",
       "text": "The feedback highlighted the importance of defining model risk in the context of influence and consequence, maintaining lifecycle performance, and improving clarity around use cases pertinent to RWE.",
       "mark": [
        0,
        199
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0034",
     "urlLabel": "Read the comment"
    },
    {
     "title": "PhRMA",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "Press report"
      }
     ],
     "quotes": [
      {
       "label": "RAPS, reporting the letter",
       "text": "“To enhance these discussions, FDA should focus on complex, high-risk AI models and share learnings across engagement options to foster consistent regulatory decision-making,” the group added.",
       "mark": [
        0,
        192
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0090",
     "urlLabel": "Read the comment"
    },
    {
     "title": "LUNGevity Foundation",
     "meta": [
      "Patient or consumer group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "The draft guidance defines the risk of an AI model based on its relative influence and decision consequence, providing one example of a risk assessment of an AI model used in clinical development.",
       "mark": [
        0,
        196
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0098",
     "urlLabel": "Read the comment"
    },
    {
     "title": "National Alliance for Hispanic Health",
     "meta": [
      "Patient or consumer group",
      "9 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "The guidance should include a specific framework for evaluating decision consequences by gender, race, ethnicity, and socioeconomic status.",
       "mark": [
        0,
        139
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0108",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Critical Path Institute",
     "meta": [
      "Academic or research institute",
      "4 April 2025"
     ],
     "tags": [
      {
       "label": "Press report"
      }
     ],
     "quotes": [
      {
       "label": "RAPS, reporting the letter",
       "text": "The Critical Path Institute (CPI) also commented on the guidance and asked FDA how it would be used to evaluate generative AI and for more clarification on the model risk matrix proposed by the agency.",
       "mark": [
        0,
        201
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0048",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Duke-Margolis Institute for Health Policy",
     "meta": [
      "Academic or research institute",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "Press report"
      }
     ],
     "quotes": [
      {
       "label": "RAPS, reporting the letter",
       "text": "“Therefore, we encourage FDA to clarify what or which types of risk should be assessed and/or offer additional examples that may further demonstrate how a multi-dimensional, risk-based framework could be applied,” the organization added.",
       "mark": [
        0,
        237
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0101",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Elvan Ceyhan",
     "meta": [
      "Academic or research institute",
      "6 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "The model risk matrix provides a useful framework, but the guidance does not explain how sponsors should document model influence assessments.",
       "mark": [
        0,
        142
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0061",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Rominder Singh (Northeastern University)",
     "meta": [
      "Academic or research institute",
      "16 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Recommendations: Referring to the FDA DHAC meeting in 2024—which focused on generative AI in medical devices—it would be helpful to include discussion on premarket evaluation, risk management, and postmarket monitoring.",
       "mark": [
        0,
        219
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0111",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Tomo Lazovich",
     "meta": [
      "Academic or research institute",
      "1 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "1) release further guidance on risk assessment that taxonomizes risk and imposes stringent requirements on any models that make predictions about humans; 2) revise guidance to clarify that informed consent requires that study participants be informed of any risks associated with the use of AI during the trial and that their data can only be used to train AI with their consent; and",
       "mark": [
        3,
        152
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0026",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Ajay Babu Pazhayattil",
     "meta": [
      "Individual",
      "6 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Measuring fill volume through release testing would reduce the AI model influence, and therefore, the model influence would be determined to be low.",
       "mark": [
        0,
        148
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0058",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Anonymous (0029)",
     "meta": [
      "Individual",
      "31 March 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "The guidance describes COU broadly but does not define specific COU levels (e.g., high-risk vs. low-risk categories) with concrete examples.",
       "mark": [
        0,
        140
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0029",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Anonymous (0031)",
     "meta": [
      "Individual",
      "2 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "…the areas where ML algorithms would be acceptable for use and suggested types of ML algorithms that would be optimal - specifically areas where there would inherently be a lot of error even without the high risk of ML analysis (e.g. image/scan interpretation) or areas where a high amount of error would not impact the risk to the patients (e.g. using AI to setup non-analysis computer framework)",
       "mark": [
        118,
        227
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0031",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Fayez Rahman",
     "meta": [
      "Individual",
      "9 January 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Question: Regarding model risk, is it fair to say that the risk decreases over time since the ML component is being trained with more data so there should be less bias moving forward therefore periodic review can decrease in frequency, and dependency on release can be increased?",
       "mark": [
        0,
        279
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0010",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Lamia Anwar",
     "meta": [
      "Individual",
      "30 September 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "The proposed 7-step framework is valuable, but the model risk matrix lacks objective scoring criteria for categorizing low, medium, or high risk.",
       "mark": [
        0,
        145
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0116",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Sharif Hoque",
     "meta": [
      "Individual",
      "7 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "It would be helpful to provide a example of low model risk (Page 9, Line 260).",
       "mark": [
        0,
        78
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0104",
     "urlLabel": "Read the comment"
    }
   ],
   "note": "20 of 48 readable submitters"
  },
  {
   "id": "llms",
   "label": "Rules for large language models",
   "count": 12,
   "records": [
    {
     "title": "George Evgrafov",
     "meta": [
      "Individual",
      "6 April 2025",
      "10 comments"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "The draft omits discussion of publicly available AI foundation models, which represent a growing class of tools used by sponsors and service providers in regulated environments.",
       "mark": [
        0,
        177
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0054",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Dr. Reddy's Laboratories",
     "meta": [
      "Drug or biotech company",
      "6 June 2026"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "In non-GMP operations, Generative AI and Large Language Models may be used, where it will not impact on patient safety, product quality and data integrity.",
       "mark": [
        0,
        155
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0126",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Consumer Technology Association",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "We understand that the agency is still developing its approach to regulating generative AI-enabled medical devices and has recognized that medical devices that utilize general foundation models may present unique regulatory considerations.",
       "mark": [
        0,
        239
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0085",
     "urlLabel": "Read the comment"
    },
    {
     "title": "International Society for Pharmacoepidemiology",
     "meta": [
      "Trade or professional group",
      "3 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Summary of its letter, on its website",
       "text": "We encouraged the FDA to clarify its terminology by aligning definitions of AI and machine learning (ML) with those in the Agency’s existing Digital Health and Artificial Intelligence Glossary and to clarify the scope of AI models referenced, including whether it encompasses generative AI and foundation models such as GPT-4.",
       "mark": [
        253,
        325
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0034",
     "urlLabel": "Read the comment"
    },
    {
     "title": "RWE Alliance",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Letter, as posted on its website",
       "text": "We suggest FDA expand its sections on credibility assessments and life cycle management to include examples for self-learning models, foundation models, and generative AI.",
       "mark": [
        0,
        171
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0084",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Advarra",
     "meta": [
      "CRO, vendor or consultancy",
      "7 April 2025"
     ],
     "tags": [
      {
       "label": "From its website"
      }
     ],
     "quotes": [
      {
       "label": "Summary of its letter, on its website",
       "text": "While the draft guidance briefly acknowledges the evolving AI landscape, it does not yet fully address the challenges posed by the absences of governance and oversight of LLMs.",
       "mark": [
        0,
        176
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0086",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Critical Path Institute",
     "meta": [
      "Academic or research institute",
      "4 April 2025"
     ],
     "tags": [
      {
       "label": "Press report"
      }
     ],
     "quotes": [
      {
       "label": "RAPS, reporting the letter",
       "text": "The Critical Path Institute (CPI) also commented on the guidance and asked FDA how it would be used to evaluate generative AI and for more clarification on the model risk matrix proposed by the agency.",
       "mark": [
        0,
        201
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0048",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Michael Lingzhi Li",
     "meta": [
      "Academic or research institute",
      "27 February 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Uncertainty Quantification and Confidence Intervals: Unlike traditional statistical models, LLMs do not provide well-defined confidence intervals or uncertainty estimates for their outputs.",
       "mark": [
        0,
        189
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0020",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Rominder Singh (Northeastern University)",
     "meta": [
      "Academic or research institute",
      "16 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Clarifying distinctions between generative and predictive AI would also help.",
       "mark": [
        0,
        77
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0111",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Anonymous (0125)",
     "meta": [
      "Individual",
      "5 June 2026"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Specifically, (a): is AI use allowed, as long as a human takes ownership for any outputs that are used in final documents?",
       "mark": [
        0,
        122
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0125",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Fayez Rahman",
     "meta": [
      "Individual",
      "9 January 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "Question: line 47/48: Does operational efficiency include the use of LLMs to generate protocols or asking LLMs questions regarding a process CPP or CQA?",
       "mark": [
        0,
        152
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0010",
     "urlLabel": "Read the comment"
    },
    {
     "title": "Sharif Hoque",
     "meta": [
      "Individual",
      "7 April 2025"
     ],
     "tags": [],
     "quotes": [
      {
       "label": "Comment",
       "text": "May be helpful to mention how Generative AI may impact this guidance in different ways than traditional AI.",
       "mark": [
        0,
        107
       ],
       "tone": "source"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0104",
     "urlLabel": "Read the comment"
    }
   ],
   "note": "12 of 48 readable submitters"
  },
  {
   "id": "unreadable",
   "label": "Filed only an attachment we could not read",
   "count": 57,
   "records": [
    {
     "title": "AbbVie",
     "meta": [
      "Drug or biotech company",
      "7 April 2025",
      "2 comments"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file(s)",
       "tone": "source",
       "mark": [
        0,
        20
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (293 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0066",
     "urlLabel": "See the comment"
    },
    {
     "title": "BioNTech",
     "meta": [
      "Drug or biotech company",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Please see attached file",
       "tone": "source",
       "mark": [
        0,
        24
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (234 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0081",
     "urlLabel": "See the comment"
    },
    {
     "title": "Boehringer Ingelheim",
     "meta": [
      "Drug or biotech company",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file(s)",
       "tone": "source",
       "mark": [
        0,
        20
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (282 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0080",
     "urlLabel": "See the comment"
    },
    {
     "title": "Cellino Biotech",
     "meta": [
      "Drug or biotech company",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Comment from Cellino Biotech, Inc. attached.",
       "tone": "source",
       "mark": [
        35,
        43
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (55 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0077",
     "urlLabel": "See the comment"
    },
    {
     "title": "EMD Serono",
     "meta": [
      "Drug or biotech company",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file(s). Comment letter submitted by EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada. Contact person Elizabeth Rosenkrands Lange, Senior Director & Head, US Regulatory Scientific Policy.",
       "tone": "source",
       "mark": [
        0,
        20
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (302 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0078",
     "urlLabel": "See the comment"
    },
    {
     "title": "Flagship Pioneering",
     "meta": [
      "Drug or biotech company",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Please see attached.",
       "tone": "source",
       "mark": [
        0,
        19
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (224 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0099",
     "urlLabel": "See the comment"
    },
    {
     "title": "insitro",
     "meta": [
      "Drug or biotech company",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "At insitro, we are building a different kind of drug company to bring better drugs faster to the patients who can benefit most. Through the power of machine learning (ML) and data at scale, we decode the complexities of biology to unlock transformative new medicines. Detailed comments from insitro…",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (34 KB)",
       "tone": "source",
       "mark": [
        0,
        24
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0102",
     "urlLabel": "See the comment"
    },
    {
     "title": "Ipca Laboratories",
     "meta": [
      "Drug or biotech company",
      "4 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Dear Madam/Sir, Greetings from Ipca Laboratories Limited, Mumbai, India! Ipca Laboratories Ltd., a consumer-led global pharmaceutical company, creating healthy doses of life since 1949. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents…",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (5474 KB)",
       "tone": "source",
       "mark": [
        0,
        26
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0038",
     "urlLabel": "See the comment"
    },
    {
     "title": "Otsuka",
     "meta": [
      "Drug or biotech company",
      "4 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Otsuka Pharmaceutical Development & Commercialization, Inc. (see attached file)",
       "tone": "source",
       "mark": [
        61,
        78
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (1327 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0047",
     "urlLabel": "See the comment"
    },
    {
     "title": "ReciBioPharm (Arranta Bio)",
     "meta": [
      "Drug or biotech company",
      "18 March 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file.",
       "tone": "source",
       "mark": [
        0,
        17
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (575 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0021",
     "urlLabel": "See the comment"
    },
    {
     "title": "Cerebro NeuroTech",
     "meta": [
      "Device company",
      "21 February 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products Subject:Comments and Suggestions on FDA Draft Guidance Docket Number: FDA-2024-D-4689 February 2025 On behalf of Cerebro, we would like to thank the FDA for the opportunity…",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (241 KB)",
       "tone": "source",
       "mark": [
        0,
        25
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0019",
     "urlLabel": "See the comment"
    },
    {
     "title": "GE HealthCare",
     "meta": [
      "Device company",
      "18 June 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Comment from GE HealthCare",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (164 KB)",
       "tone": "source",
       "mark": [
        0,
        25
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0114",
     "urlLabel": "See the comment"
    },
    {
     "title": "American Association of Pharmaceutical Scientists",
     "meta": [
      "Trade or professional group",
      "20 March 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Please see attached spreadsheet for questions and comments from American Association of Pharmaceutical Scientists.",
       "tone": "source",
       "mark": [
        0,
        113
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: XLSX (25 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0023",
     "urlLabel": "See the comment"
    },
    {
     "title": "Animal Health Institute",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "The ANIMAL HEALTH INSTITUTE (AHI) submits these comments to Docket ID: FDA-2024-D-4689: Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products. AHI is the national trade association representing manufacturers of animal health…",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (428 KB)",
       "tone": "source",
       "mark": [
        0,
        25
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0105",
     "urlLabel": "See the comment"
    },
    {
     "title": "Association for Accessible Medicines",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Comments from the Association for Accessible Medicines (AAM): Considerations for the Use of Artificial Intelligence to Support Regulatory Decision- Making for Drug and Biological Products",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (332 KB)",
       "tone": "source",
       "mark": [
        0,
        25
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0079",
     "urlLabel": "See the comment"
    },
    {
     "title": "BioPhorum",
     "meta": [
      "Trade or professional group",
      "3 April 2025",
      "2 comments"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "BioPhorum represents the perspective of the biomanufacuting industry, which is not only at the elm of innovation for the delivery of new modalities to cure patients but also at the elm of innovative approaches,including the use if AI. BioPhorum represents over 150 biomanufacturers, their drug…",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: DOCX (1276 KB)",
       "tone": "source",
       "mark": [
        0,
        27
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0033",
     "urlLabel": "See the comment"
    },
    {
     "title": "Connected Health Initiative",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file(s)",
       "tone": "source",
       "mark": [
        0,
        20
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (214 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0089",
     "urlLabel": "See the comment"
    },
    {
     "title": "Health Innovation Alliance",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Please find attached comments from the Health Innovation Alliance",
       "tone": "source",
       "mark": [
        0,
        65
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (2245 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0094",
     "urlLabel": "See the comment"
    },
    {
     "title": "IQ Consortium",
     "meta": [
      "Trade or professional group",
      "5 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Attached please find comments from the IQ Consortium.",
       "tone": "source",
       "mark": [
        0,
        52
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (234 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0049",
     "urlLabel": "See the comment"
    },
    {
     "title": "ISCTM",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file(s)",
       "tone": "source",
       "mark": [
        0,
        20
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (267 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0076",
     "urlLabel": "See the comment"
    },
    {
     "title": "ISPE (Pharmaceutical Engineering)",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Comments from ISPE (International Society for Pharmaceutical Engineering)",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (422 KB)",
       "tone": "source",
       "mark": [
        0,
        25
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0074",
     "urlLabel": "See the comment"
    },
    {
     "title": "National Association of Manufacturers",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Please find attached the comments of the National Association of Manufacturers (NAM).",
       "tone": "source",
       "mark": [
        0,
        79
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (200 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0100",
     "urlLabel": "See the comment"
    },
    {
     "title": "Parenteral Drug Association",
     "meta": [
      "Trade or professional group",
      "2 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached comments from the Parenteral Drug Association.",
       "tone": "source",
       "mark": [
        0,
        58
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (696 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0032",
     "urlLabel": "See the comment"
    },
    {
     "title": "Pistoia Alliance",
     "meta": [
      "Trade or professional group",
      "5 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "The Pistoia Alliance is offering the attached comments in response to the draft guidance on the use of artificial intelligence to support regulatory decision-making for drug and biological products. See the attached file(s)",
       "tone": "source",
       "mark": [
        33,
        197
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: DOCX (12 KB), XLSX (10 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0050",
     "urlLabel": "See the comment"
    },
    {
     "title": "PSI and EFSPI",
     "meta": [
      "Trade or professional group",
      "4 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Please see attached the consolidated comments from PSI(UK) and EFSPI(Europe)",
       "tone": "source",
       "mark": [
        0,
        54
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: XLSX (27 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0042",
     "urlLabel": "See the comment"
    },
    {
     "title": "REMS Industry Consortium",
     "meta": [
      "Trade or professional group",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Docket No. FDA-2024-D-4689 REMS Industry Consortium Comments",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (276 KB)",
       "tone": "source",
       "mark": [
        0,
        25
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0096",
     "urlLabel": "See the comment"
    },
    {
     "title": "SILICA",
     "meta": [
      "Trade or professional group",
      "4 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "The SILICA association thanks the FDA for this useful draft guidance, which contributes to a better anticipation and mitigation of the potential risks induced by the use of AI in the drug product lifecycle, and for the opportunity to provide comments. Please see SILICA's comments in the attached…",
       "tone": "source",
       "mark": [
        284,
        297
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (254 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0039",
     "urlLabel": "See the comment"
    },
    {
     "title": "Society of Quality Assurance",
     "meta": [
      "Trade or professional group",
      "6 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Attached please find comments from the Society of Quality Assurance.",
       "tone": "source",
       "mark": [
        0,
        67
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (270 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0052",
     "urlLabel": "See the comment"
    },
    {
     "title": "Amazon Web Services",
     "meta": [
      "CRO, vendor or consultancy",
      "4 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Thank you for considering our attached comments.",
       "tone": "source",
       "mark": [
        26,
        47
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (167 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0043",
     "urlLabel": "See the comment"
    },
    {
     "title": "Certara",
     "meta": [
      "CRO, vendor or consultancy",
      "3 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Certara welcomes the opportunity to comment on the FDA guideline, our comments are provided in the attached document",
       "tone": "source",
       "mark": [
        95,
        116
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (215 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0035",
     "urlLabel": "See the comment"
    },
    {
     "title": "CIMCON Software",
     "meta": [
      "CRO, vendor or consultancy",
      "5 May 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "At CIMCON, we have been working with firms to help them comply with an ever-evolving regulatory landscape for over 25 years. We believe this guidance is a great step forward in clarifying how firms should handle the risk that comes from AI, but have a few suggestions for additional clarification…",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (230 KB)",
       "tone": "source",
       "mark": [
        0,
        25
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0113",
     "urlLabel": "See the comment"
    },
    {
     "title": "Clario",
     "meta": [
      "CRO, vendor or consultancy",
      "4 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Please see attached file.",
       "tone": "source",
       "mark": [
        0,
        24
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (197 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0036",
     "urlLabel": "See the comment"
    },
    {
     "title": "Florence Healthcare",
     "meta": [
      "CRO, vendor or consultancy",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Feedback attached",
       "tone": "source",
       "mark": [
        9,
        17
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (115 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0087",
     "urlLabel": "See the comment"
    },
    {
     "title": "GATC Health",
     "meta": [
      "CRO, vendor or consultancy",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "GATC Health Corp is a technology company that is transforming drug discovery and development through its AI-driven platform and approach. The company’s validated and proprietary Multiomics Advanced Technology(TM) (MAT) simulates human biochemistry’s billions of interactions to rapidly create novel…",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (801 KB), PDF (76 KB), PDF (158 KB), PDF (297 KB), PDF (301 KB), PDF (173 KB), PDF (164 KB), PDF (309 KB)",
       "tone": "source",
       "mark": [
        0,
        122
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0092",
     "urlLabel": "See the comment"
    },
    {
     "title": "Global Key Solutions",
     "meta": [
      "CRO, vendor or consultancy",
      "6 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Refer to the attachment 1 for Global Key Solutions Corp. comments on the entire document, Docket Number FDA-2024-D-4689, “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products; Draft Guidance for Industry; Availability; Agency…",
       "tone": "source",
       "mark": [
        0,
        55
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (337 KB), XLSX (14 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0059",
     "urlLabel": "See the comment"
    },
    {
     "title": "Halloran Consulting Group",
     "meta": [
      "CRO, vendor or consultancy",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Halloran Comments",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: DOCX (123 KB)",
       "tone": "source",
       "mark": [
        0,
        26
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0106",
     "urlLabel": "See the comment"
    },
    {
     "title": "Owkin",
     "meta": [
      "CRO, vendor or consultancy",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file.",
       "tone": "source",
       "mark": [
        0,
        17
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (113 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0068",
     "urlLabel": "See the comment"
    },
    {
     "title": "Simulations Plus",
     "meta": [
      "CRO, vendor or consultancy",
      "28 March 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file(s)",
       "tone": "source",
       "mark": [
        0,
        20
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: DOCX (18 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0027",
     "urlLabel": "See the comment"
    },
    {
     "title": "TriApex Laboratories",
     "meta": [
      "CRO, vendor or consultancy",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file(s)",
       "tone": "source",
       "mark": [
        0,
        20
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: DOCX (19 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0063",
     "urlLabel": "See the comment"
    },
    {
     "title": "VeriSIM Life",
     "meta": [
      "CRO, vendor or consultancy",
      "28 March 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file(s)",
       "tone": "source",
       "mark": [
        0,
        20
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (117 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0028",
     "urlLabel": "See the comment"
    },
    {
     "title": "Cruelty Free International",
     "meta": [
      "Patient or consumer group",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Please see attached comments from Cruelty Free International.",
       "tone": "source",
       "mark": [
        0,
        60
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (207 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0091",
     "urlLabel": "See the comment"
    },
    {
     "title": "ForHumanity",
     "meta": [
      "Patient or consumer group",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "ForHumanity, a non-profit public charity whose mission is to examine and analyze downside risk associated with the ubiquitous advance of AI, algorithmic and autonomous systems and where possible to engage in risk mitigation to maximize the benefits of these systems... ForHumanity. Our comments are…",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (286 KB)",
       "tone": "source",
       "mark": [
        0,
        25
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0062",
     "urlLabel": "See the comment"
    },
    {
     "title": "Friends of Cancer Research",
     "meta": [
      "Patient or consumer group",
      "4 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Please see attached comments from Friends of Cancer Research.",
       "tone": "source",
       "mark": [
        0,
        60
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (152 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0040",
     "urlLabel": "See the comment"
    },
    {
     "title": "Humane World for Animals",
     "meta": [
      "Patient or consumer group",
      "4 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Please see attached file.",
       "tone": "source",
       "mark": [
        0,
        24
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (269 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0041",
     "urlLabel": "See the comment"
    },
    {
     "title": "National Multiple Sclerosis Society",
     "meta": [
      "Patient or consumer group",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Please see the attached comments from the National Multiple Sclerosis Society on the FDA's Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry and Other Interested Parties",
       "tone": "source",
       "mark": [
        0,
        266
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (209 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0095",
     "urlLabel": "See the comment"
    },
    {
     "title": "World Privacy Forum",
     "meta": [
      "Patient or consumer group",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Attached please find the comments of the World Privacy Forum regarding Docket No. FDA-2024-D-4689.",
       "tone": "source",
       "mark": [
        0,
        80
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (442 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0103",
     "urlLabel": "See the comment"
    },
    {
     "title": "Digital CMC CERSI (University of Strathclyde)",
     "meta": [
      "Academic or research institute",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Dear Sir/Madam The Centre of Excellence for Regulation Science and Innovation (CERSI) for the Digital Transformation of Medicines Development and Manufacturing is grateful for the opportunity to provide feedback on the referenced draft guidance. This UK based CERSI is a newly established centre…",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (101 KB)",
       "tone": "source",
       "mark": [
        0,
        25
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0064",
     "urlLabel": "See the comment"
    },
    {
     "title": "IMI Big Picture project",
     "meta": [
      "Academic or research institute",
      "28 March 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file(s)",
       "tone": "source",
       "mark": [
        0,
        20
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (101 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0025",
     "urlLabel": "See the comment"
    },
    {
     "title": "Andrea Sikora",
     "meta": [
      "Individual",
      "1 June 2026"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Please see the attached file re: Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products",
       "tone": "source",
       "mark": [
        0,
        157
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (388 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0124",
     "urlLabel": "See the comment"
    },
    {
     "title": "Anonymous (0002)",
     "meta": [
      "Individual",
      "7 January 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file(s)",
       "tone": "source",
       "mark": [
        0,
        20
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (73 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0002",
     "urlLabel": "See the comment"
    },
    {
     "title": "Anonymous (academia) (0093)",
     "meta": [
      "Individual",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file(s)",
       "tone": "source",
       "mark": [
        0,
        20
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (56 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0093",
     "urlLabel": "See the comment"
    },
    {
     "title": "Fahimeh Mirakhori",
     "meta": [
      "Individual",
      "10 February 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file(s)",
       "tone": "source",
       "mark": [
        0,
        20
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (760 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0016",
     "urlLabel": "See the comment"
    },
    {
     "title": "Ildiko Ziegler",
     "meta": [
      "Individual",
      "2 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Comments on docket number: FDA-2024-D-4689 Draft Guidance for Industry and Other Interested Parties Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products (January 2025) Dear Commissioner Dr. Califf, Dear Dockets Management…",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (169 KB)",
       "tone": "source",
       "mark": [
        0,
        25
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0030",
     "urlLabel": "See the comment"
    },
    {
     "title": "Jason Hsu",
     "meta": [
      "Individual",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "Please see the attachment.",
       "tone": "source",
       "mark": [
        0,
        25
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (180 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0075",
     "urlLabel": "See the comment"
    },
    {
     "title": "JM",
     "meta": [
      "Individual",
      "7 April 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "FDA-2024-D-4689",
       "tone": "source"
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (385 KB)",
       "tone": "source",
       "mark": [
        0,
        25
       ]
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0065",
     "urlLabel": "See the comment"
    },
    {
     "title": "K S",
     "meta": [
      "Individual",
      "9 January 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file(s)",
       "tone": "source",
       "mark": [
        0,
        20
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (412 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0005",
     "urlLabel": "See the comment"
    },
    {
     "title": "Manfred Stapff",
     "meta": [
      "Individual",
      "16 January 2025"
     ],
     "quotes": [
      {
       "label": "Comment box",
       "text": "See attached file(s)",
       "tone": "source",
       "mark": [
        0,
        20
       ]
      },
      {
       "label": "Regulations.gov record",
       "text": "Attachments: PDF (321 KB)",
       "tone": "context"
      }
     ],
     "url": "https://www.regulations.gov/comment/FDA-2024-D-4689-0012",
     "urlLabel": "See the comment"
    }
   ],
   "note": "57 of 108 submitters, 10 of them drug or biotech companies, listed first"
  }
 ],
 "download": "Every card is in the {json}, and every comment with its codes is in the CSV below."
}
